Handheld fingertip device delivers clinical-grade readings — no cuff, no calibration, no compromise.

The NMPA designation advances NHWD-870 HCI, an oral BET inhibitor for advanced thoracic NUT carcinoma, following Phase II data showing anti-tumour activity and survival benefit in a rare, aggressive cancer with limited treatment options.